STB
ALNY icon

S&T Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

S&T Bank’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.61K Sell
12
-26
-68% -$7.84K ﹤0.01% 360
2026
Q1 		$12.6K Buy
38
+27
+245% +$9.19K ﹤0.01% 261
2025
Q4 		$4.37K Sell
11
-4
-27% -$1.77K ﹤0.01% 304
2025
Q3 		$6.84K Hold
15
– – ﹤0.01% 283
2025
Q2 		$4.89K Buy
15
+9
+150% +$2.49K ﹤0.01% 290
2025
Q1 		$1.62K Buy
+6
New +$1.54K ﹤0.01% 326

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

S&T Bank's ALNY Position: Q2 2026 in Review

S&T Bank reduced its Alnylam Pharmaceuticals (ALNY) stake by 68% in Q2 2026, selling an estimated $7.84K and leaving 12 shares worth $3.61K. The position accounts for ﹤0.01% of the portfolio, ranked #360.

S&T Bank first reported a position in ALNY in Q1 2025 and has held it in 6 quarters since. The position peaked at $12.6K in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • S&T Bank held 12 shares of Alnylam Pharmaceuticals worth $3.61K as of Q2 2026.
  • S&T Bank sold 26 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $7.84K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of S&T Bank's portfolio in Q2 2026, its #360 holding.
  • S&T Bank first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • S&T Bank's Alnylam Pharmaceuticals position peaked at $12.6K in Q1 2026.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on S&T Bank's 13F filing for Q2 2026, filed 12 Aug 2026.